The effect of a bitter compound on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects

Phase 1

• Conditions: The study is meant to have a better understanding in obesity and how we can prevent/cure it. Therefore, the product will first be tested in healthy, lean volunteers.; MedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disorders; Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]

• Registration Number: EUCTR2018-003083-30-BE
• Lead Sponsor: Z Leuven

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-01-02
• Study Completion: 2020-10-22
• Last Update Posted: 5 April 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 10

Inclusion Criteria

Subject is female between 18 and 65 years of age.
Subject has a BMI between 18 and 25 kg/m² and has a stable body weight for at least 3 consecutive months at the start of the study and keeps a stable weight during the study visits.
Subject is allowed to take 2 Plaquenil capsuls for one visit with a maximal dose of 6.5 mg hydroxychloroquine sulphate per kg bodyweight.
Women of child-bearing potential agree to apply during the entire duration of the trial a highly effective method of birth control, which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, or some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. Women of non-childbearing potential may be included if surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses.
Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Subject is under age of legal consent, male, pregnant or breastfeeding.
Subject with a BMI = 18 kg/m² or BMI = 25 kg/m².
Subject weight less than 62 kg.
Subject is currently following a weight loss diet.
Subject has current symptoms or a history of gastrointestinal or other significant somatic or psychiatric diseases or drug allergies.
Subject has diabetes.
Subject has a significant heart, lung, liver or kidney disease.
Subject has any history of a neurological disorder.
Subject has a history of abdominal surgery. Those having undergone a simple appendectomy more than 1 year prior to the screening visit may participate.
Subject has retinopathy.
Subject suffers from psoriasis.
Subject has porphyria.
Subject shows abnormal eating behavior or has an eating disorder.
History or current use of drugs that can affect glycaemia, gastrointestinal function, motility or sensitivity or gastric acidity.
History or current use of centrally acting medication, including antidepressants, antipsychotics and/or benzodiazepines (in the last year before screening visit).
Subject consumes excessive amounts of alcohol, defined as >14 units per week for women and >21 units per week for men.
Subject is currently (defined as within approximately 1 year of the screening visit) a regular or irregular user (including recreational use”) of any illicit drugs (including marijuana) or has a history of drug (including alcohol) abuse. Further, patient is unwilling to refrain from the use of drugs during this study.
High caffeine intake (> 4 cups of coffee daily or equivalent).
Inability or unwillingness to perform all of the study procedures, or the subject is considered unsuitable in any way by the principal investigator.
Recent participation (<30 days) or simultaneous participation in another clinical study.
Subjects with lactose intolerance.
Subjects with quinine allergy.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified